Discover more from Unacceptable Jessica
What's VAERS saying?
It was brought to my attention today from one of my readers that a rare blood cancer that affects B cells called Waldenström macroglobulinemia (lymphoma) is affecting people she knows who were injected with the COVID-19 products.
It is a rare type of non-Hodgkin’s lymphoma that leads to high levels of IgM to yield thick ‘jelly-like’ blood. Sound familiar?
It can manifest in blood vessel damage, bleeding, neuropathy, enlarged organs, anemia, retinal damage leading to blurred vision, fatigue, enlarged organs and swollen lymph nodes.
Here’s a good video synopsis.
People who are unfortunate enough to be affected have been found to have mutations in the MYD88 gene and/or the CXCR4 gene. They are typically caucasian males over 50. A complete blood count is useful for confirming a diagnosis. Plasmapheresis is a useful technique to remove excess IgM.
I checked in VAERS, and I was surprised to find that there are 49 reports of Waldenstrom’s. 37 of these reports did not involve a history.
There are 37 cases filed to VAERS for an extremely rare cancer with an acute occurrence.
The people who filed reports have an average age of 73 years and are 51% male. VAERS data that we have access to doesn’t get into ethnicity. You’d have to ask the CDC to show you the real books to get that level of detail.
So yes, older individuals are reporting but only half of them are male.
Just as a reminder, if we account for the under-reporting factor, let’s say 31, we have 1,519 reports.
Waldenström macroglobulinemia is a rare disorder and there are fewer than 1,500 cases occurring in the United States annually.1 Since we’ve got 1,519 reports in VAERS, we are there already in the context of a single injectable product. 92% of these reports involve injections given in 2021, so these represent one year.